Notably, c‐Myc‐i7 demonstrated an exceptional approximately 40‐fold increase in effectiveness against prostate cancer (IC50 of 2.5 μM) when compared to 10058‐F4 (IC50 of 95.2 μM). This evidence concerns the gene MYC and Familial prostate cancer.